DS
ACAD icon

DRW Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

DRW Securities’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200K Buy
+8,993
New +$215K ﹤0.01% 1119
2025
Q3 		– Sell
-10,047
Closed -$222K – 1255
2025
Q2 		$222K Buy
+10,047
New +$187K 0.01% 907

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

DRW Securities's ACAD Position: Q1 2026 in Review

DRW Securities opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 8,993 shares worth $200K. The stake represents ﹤0.01% of the portfolio and ranks #1119 among its holdings. This is a return to the name: DRW Securities previously reported a position in ACAD as recently as Q2 2025.

DRW Securities first reported a position in ACAD in Q2 2025 and has held it in 2 quarters since. The position peaked at $222K in Q2 2025. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • DRW Securities held 8,993 shares of Acadia Pharmaceuticals worth $200K as of Q1 2026.
  • Acadia Pharmaceuticals was a new DRW Securities position in Q1 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of DRW Securities's portfolio in Q1 2026, its #1119 holding.
  • DRW Securities first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • DRW Securities's Acadia Pharmaceuticals position peaked at $222K in Q2 2025.
  • 342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.